Prognostic Value of β-catenin Expression in Breast Cancer Patients: a Meta-analysis

  • Zhang, De-Pu (Department of Obstetrics and Gynecology, Peking Union Medical College Hospital) ;
  • Li, Xiao-Wei (Department of Thoracic Surgery, Provincial Hospital Affiliated to Shandong University) ;
  • Lang, Jing-He (Department of Obstetrics and Gynecology, Peking Union Medical College Hospital)
  • Published : 2015.09.02


Background: ${\beta}$-catenin plays a crucial role in the progression of breast cancer (BC) and a prognostic role of in BC patients has been widely reported. However, controversy still remains. Materials and Methods: Identical search strategies were used to search relevant literature in electronic databases updated to July 1, 2014. Individual hazard ratios (HRs) and 95% confidence intervals (CIs) were extracted and pooled HRs with 95%CIs were used to evaluate the strength of association between positive ${\beta}$-catenin expression in different subcellular locations and survival results of BC patients. Subgroup and meta-regression analyses were performed to explore heterogeneity. Funnel plots of Begg's and Egger's linear regression test were used to investigate publication bias. Heterogeneity and sensitivity were also assessed. All the work was completed using STATA. Results: A total of 2,204 patients from 12 evaluative studies were finally included. Pooled HRs and 95%CIs suggested that ${\beta}$-catenin expression in cytoplasm/nucleus had an unfavorable impact on both overall survival (OS) (HR: 1.93, 95%CI: 1.40-2.65) and disease free survival (DFS)/ recurrent free survival (RFS) (HR: 1.60, 95%CI: 1.20-2.13) in BC patients. However, here was no significant association between ${\beta}$-catenin expression in the membranes with OS (HR: 0.65, 95%CI: 0.42-1.02) or DFS/RFS (HR: 0.66, 95%CI: 0.38-1.13). Publication bias was absent in all of the four outcomes. Sensitivity analysis revealed that the results of this meta-analysis were robust. Conclusions: Positive ${\beta}$-catenin expression in cytoplasm/nucleus rather than in membrane is a significant prognostic factor in patients with BC who have been surgically treated.


  1. Cheng CW, Liu YF, Yu JC, et al (2012). Prognostic significance of cyclin D1, beta-catenin, and MTA1 in patients with invasive ductal carcinoma of the breast. Ann Surg Oncol, 19, 4129-39.
  2. Chung GG, Zerkowski MP, Ocal IT, et al (2004). beta-Catenin and p53 analyses of a breast carcinoma tissue microarray. Cancer, 100, 2084-92.
  3. Colozza M, Azambuja E, Cardoso F, et al (2005). Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol, 16, 1723-39.
  4. Coradini D, Daidone MG (2004). Biomolecular prognostic factors in breast cancer. Curr Opin Obstet Gynecol, 16, 49-55.
  5. Dolled-Filhart M, McCabe A, Giltnane J, et al (2006). Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res, 66, 5487-94.
  6. Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.
  7. Fanelli MA, Montt-Guevara M, Diblasi AM, et al (2008). P-cadherin and beta-catenin are useful prognostic markers in breast cancer patients; beta-catenin interacts with heat shock protein Hsp27. Cell Stress Chaperones, 13, 207-20.
  8. Geyer FC, Lacroix-Triki M, Savage K, et al (2011). beta-Catenin pathway activation in breast cancer is associated with triplenegative phenotype but not with CTNNB1 mutation. Mod Pathol, 24, 209-31.
  9. Gillett CE, Miles DW, Ryder K, et al (2001). Retention of the expression of E-cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast. J Pathol, 193, 433-41.
  10. Hayes DF (2005). Prognostic and predictive factors revisited. Breast, 14, 493-9.
  11. Hayes MJ, Thomas D, Emmons A, et al (2008). Genetic changes of Wnt pathway genes are common events in metaplastic carcinomas of the breast. Clin Cancer Res, 14, 4038-44.
  12. Ho SK, Thike AA, Cheok PY, et al (2013). Phyllodes tumours of the breast: the role of CD34, vascular endothelial growth factor and beta-catenin in histological grading and clinical outcome. Histopathology, 63, 393-406.
  13. Incassati A, Chandramouli A, Eelkema R, et al (2010). Key signaling nodes in mammary gland development and cancer: beta-catenin. Breast Cancer Res, 12, 213.
  14. Ioannidis JP, Patsopoulos NA, Evangelou E (2007). Uncertainty in heterogeneity estimates in meta-analyses. BMJ, 335, 914-6.
  15. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
  16. Jonsson M, Borg A, Nilbert M, et al (2000). Involvement of adenomatous polyposis coli (APC)/beta-catenin signalling in human breast cancer. Eur J Cancer, 36, 242-8.
  17. Khramtsov AI, Khramtsova GF, Tretiakova M, et al (2010). Wnt/beta-catenin pathway activation is enriched in basallike breast cancers and predicts poor outcome. Am J Pathol, 176, 2911-20.
  18. Kim HS, Kim GY, Kim YW, et al (2010). Stromal CD10 expression and relationship to the E-cadherin/beta-catenin complex in breast carcinoma. Histopathology, 56, 708-19.
  19. Lee BL, Liedke PE, Barrios CH, et al (2012). Breast cancer in Brazil: present status and future goals. Lancet Oncol, 13, 95-102.
  20. Li S, Li S, Sun Y, et al (2014). The expression of beta-catenin in different subtypes of breast cancer and its clinical significance. Tumour Biol.
  21. Lim SC, Lee MS (2002). Significance of E-cadherin/betacatenin complex and cyclin D1 in breast cancer. Oncol Rep, 9, 915-28.
  22. Lin SY, Xia W, Wang JC, et al (2000). Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci U S A, 97, 4262-6.
  23. Logullo AF, Nonogaki S, Pasini FS, et al (2010). Concomitant expression of epithelial-mesenchymal transition biomarkers in breast ductal carcinoma: association with progression. Oncol Rep, 23, 313-20.
  24. Lopez-Knowles E, Zardawi SJ, McNeil CM, et al (2010). Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients. Cancer Epidemiol Biomarkers Prev, 19, 301-9.
  25. Maxwell L, Santesso N, Tugwell PS, et al (2006). Method guidelines for Cochrane Musculoskeletal Group systematic reviews. J Rheumatol, 33, 2304-11.
  26. Millett GA, Flores SA, Marks G, et al (2008). Circumcision status and risk of HIV and sexually transmitted infections among men who have sex with men: a meta-analysis. Jama, 300, 1674-84.
  27. Mukherjee N, Bhattacharya N, Alam N, et al (2012). Subtypespecific alterations of the Wnt signaling pathway in breast cancer: clinical and prognostic significance. Cancer Sci, 103, 210-20.
  28. Nakopoulou L, Mylona E, Papadaki I, et al (2006). Study of phospho-beta-catenin subcellular distribution in invasive breast carcinomas in relation to their phenotype and the clinical outcome. Mod Pathol, 19, 556-63.
  29. Ozaki S, Ikeda S, Ishizaki Y, et al (2005). Alterations and correlations of the components in the Wnt signaling pathway and its target genes in breast cancer. Oncol Rep, 14, 1437-43.
  30. Pang H, Lu H, Song H, et al (2013). Prognostic values of osteopontin-c, E-cadherin and beta-catenin in breast cancer. Cancer Epidemiol, 37, 985-92.
  31. Paredes J, Correia AL, Ribeiro AS, et al (2008). Breast carcinomas that co-express E- and P-cadherin are associated with p120-catenin cytoplasmic localisation and poor patient survival. J Clin Pathol, 61, 856-62.
  32. Park D, Karesen R, Axcrona U, et al (2007). Expression pattern of adhesion molecules (E-cadherin, alpha-, beta-, gammacatenin and claudin-7), their influence on survival in primary breast carcinoma, and their corresponding axillary lymph node metastasis. Apmis, 115, 52-65.
  33. Parmar MK, Torri V, Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34.<2815::AID-SIM110>3.0.CO;2-8
  34. Prosperi JR, Goss KH (2010). A Wnt-ow of opportunity: targeting the Wnt/beta-catenin pathway in breast cancer. Curr Drug Targets, 11, 1074-88.
  35. Ryo A, Nakamura M, Wulf G, et al (2001). Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC. Nat Cell Biol, 3, 793-801.
  36. Sadot E, Conacci-Sorrell M, Zhurinsky J, et al (2002). Regulation of S33/S37 phosphorylated beta-catenin in normal and transformed cells. J Cell Sci, 115, 2771-80.
  37. Saurel CA, Patel TA, Perez EA (2010). Changes to adjuvant systemic therapy in breast cancer: a decade in review. Clin Breast Cancer, 10, 196-208.
  38. Stang A (2010). Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 25, 603-5.
  39. Tierney JF, Stewart LA, Ghersi D, et al (2007). Practical methods for incorporating summary time-to-event data into metaanalysis. Trials, 8, 16.
  40. Wang S, Li W, Lv S, et al (2011). Abnormal expression of Nek2 and beta-catenin in breast carcinoma: clinicopathological correlations. Histopathology, 59, 631-42.
  41. Weissenbacher T, Hirte E, Kuhn C, et al (2013). Multicentric and multifocal versus unifocal breast cancer: differences in the expression of E-cadherin suggest differences in tumor biology. BMC Cancer, 13, 361.
  42. Wells G SB, O'Connell D The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses. Ottawa Health Research Institute Web site, http://, Accessed 26 June 2012.
  43. Williamson PR, Smith CT, Hutton JL, et al (2002). Aggregate data meta-analysis with time-to-event outcomes. Stat Med, 21, 3337-51.
  44. Xu WH, Liu ZB, Yang C, et al (2012). Expression of dickkopf-1 and beta-catenin related to the prognosis of breast cancer patients with triple negative phenotype. PLoS One, 7, 37624.
  45. Ye N, Wang B, Quan ZF, et al (2014). The research progress of the interactions between miRNA and Wnt/beta-catenin signaling pathway in breast cancer of human and mice. Asian Pac J Cancer Prev, 15, 1075-9.
  46. ZZ H, WQ C, CX W, et al (2012). Incidence and mortality of female breast cancer in China-a report from 32 Chinese cancer registries. Tumor, 435-9.

Cited by

  1. Astrocyte elevated gene-1 promotes the proliferation and invasion of breast cancer cells by activating the Wnt/β-catenin signaling pathway vol.13, pp.4, 2017,
  2. SIRT6 Is Involved in the Progression of Ovarian Carcinomas via β-Catenin-Mediated Epithelial to Mesenchymal Transition vol.8, pp.2234-943X, 2018,